Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index; 18 of the 27 sources its claims cite were checked for support.
Abstract
People with type 2 diabetes and chronic kidney disease have a high risk for kidney failure and cardiovascular (CV) complications. Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors (SGLT2i) independently reduce CV and kidney events. The effect of combining both is unclear. FLOW trial participants with type 2 diabetes and chronic kidney disease were stratified by baseline SGLT2i use ( N = 550) or no use ( N = 2,983) and randomized to semaglutide/placebo. The primary outcome was a composite of kidney failure, ≥50% estimated glomerular filtration rate reduction, kidney death or CV death. The risk of the primary outcome was 24% lower in all participants treated with semaglutide versus placebo (95% confidence interval: 34%, 12%). The primary outcome occurred in 41/277 (semaglutide) versus 38/273 (placebo) participants on SGLT2i at baseline (hazard ratio 1.07; 95% confidence interval: 0.69, 1.67; P = 0.755) and in 290/1,490 versus 372/1,493 participants not taking SGLT2i at baseline (hazard ratio 0.73; 0.63, 0.85; P < 0.001; P interaction 0.109). Three confirmatory secondary outcomes were predefined. Treatment differences favoring semaglutide for total estimated glomerular filtration rate slope (ml min −1 /1.73 m 2 /year) were 0.75 (−0.01, 1.5) in the SGLT2i subgroup and 1.25 (0.91, 1.58) in the non-SGLT2i subgroup, P interaction 0.237. Semaglutide benefits on major CV events and all-cause death were similar regardless of SGLT2i use ( P interaction 0.741 and 0.901, respectively). The benefits of semaglutide in reducing kidney outcomes were consistent in participants with/without baseline SGLT2i use; power was limited to detect smaller but clinically relevant effects. ClinicalTrials.gov identifier: NCT03819153 .
Overview
CoChat Summary
TL;DR
In a prespecified FLOW trial analysis, semaglutide reduced kidney and cardiovascular outcomes in participants with type 2 diabetes and chronic kidney disease, with no clear heterogeneity by baseline SGLT2 inhibitor use. The SGLT2i subgroup was small, so the analysis was underpowered to detect smaller but clinically relevant interactions.
Key findings
- The primary composite outcome occurred in 41/277 (14.8%) semaglutide vs 38/273 (13.9%) placebo participants on baseline SGLT2i (HR 1.07; 95% CI 0.69, 1.67; P = 0.755), and in 290/1,490 (19.5%) vs 372/1,493 (24.9%) without baseline SGLT2i (HR 0.73; 95% CI 0.63, 0.85; P < 0.001; P interaction 0.109).
- Treatment differences favoring semaglutide for total eGFR-creatinine slope were 0.75 ml min−1/1.73 m2/year (95% CI −0.01, 1.50) with baseline SGLT2i and 1.25 ml min−1/1.73 m2/year (95% CI 0.91, 1.58) without baseline SGLT2i (P interaction 0.237).
- Semaglutide benefits on MACE and all-cause death were similar regardless of baseline SGLT2i use (P interaction 0.741 and 0.901, respectively).
- UACR was lowered by semaglutide vs placebo at week 104 by 24% (95% CI 4%, 39%) with baseline SGLT2i and 34% (95% CI 26%, 40%) without baseline SGLT2i (P interaction 0.279).
Methods
- Prespecified analysis of the FLOW trial, a randomized, double-blind, placebo-controlled, international, multicenter kidney outcomes trial in participants with type 2 diabetes and chronic kidney disease.
- 3,533 participants were randomized to semaglutide 1.0 mg once weekly or placebo; randomization was stratified by baseline SGLT2i use: 550 reported baseline SGLT2i use (277 semaglutide, 273 placebo) and 2,983 did not.
- Time-to-event outcomes used stratified Cox proportional hazards models with treatment and SGLT2i subgroup interaction terms; eGFR slopes used linear random regression, and continuous endpoints used ANCOVA with multiple imputation for missing values.
Limitations
- The paper states that power was limited because only 15.6% of randomized participants used SGLT2i at baseline, so small but clinically relevant interactions may not have been detected; the study was not designed to test specific subgroups.
- The paper states that post-baseline SGLT2i initiations were not controlled and more participants initiated SGLT2i in the placebo group.
- The text makes evident that no adjustment for multiplicity or alpha-protection was performed, and the median follow-up of 3.4 years may be too short to examine kidney outcomes beyond eGFR and UACR in the relatively small baseline SGLT2i cohort.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures











Verification
Claims the paper makes
13 Valid · 1 Not valid · 4 Not checked · 65 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors (SGLT2i) independently reduce CV and kidney events.”
§ Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial > Abstract
What the sources say
- Supportedcites [1] Sattar, N. et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 9, 653–662 (2021). source
The Added value of this study section reports that GLP-1 receptor agonists reduced major adverse cardiovascular events and a composite kidney outcome in patients with type 2 diabetes. This supports the part of the citing sentence attributed to this source. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [2] Tuttle, K. R. et al. Clinical outcomes by albuminuria status with dulaglutide versus insulin glargine in participants with diabetes and CKD: AWARD-7 exploratory analysis. Kidney360 2, 254–262 (2021). source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“The FLOW trial8 recently reported that in participants with T2D and CKD, semaglutide 1.0 mg once weekly reduced the risk of major kidney disease events by 24% and blunted eGFR decline by 1.16 ml min−1/1.73 m2/year4.”
§ Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial > Discussion
What the sources say
- Not checked — no full text of the sourcecites [4] Perkovic, V. et al. Effect of semaglutide on kidney, cardiovascular, and mortality outcomes in people with type 2 diabetes and chronic kidney disease. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2403347 (2024). source
- Could not verifycites [8] Rossing, P. et al. The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease. Nephrol. Dial. Transpl. 38, 2041–2051 (2023). sourceExperimental — accuracy not yet measured
The Abstract and Results report FLOW’s design and baseline characteristics, not treatment outcomes. Statistical considerations identifies annual eGFR change as a planned endpoint, but our copy does not report the claimed 1.16 ml/min/1.73 m²/year difference (searched for that value and the eGFR slope treatment difference). (LLM, conf=0.75)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors (SGLT2i) independently reduce CV and kidney events.”
- Also stated in: § Main · boosted
“Later, three independent trials with SGLT2i in persons with and without T2D and CKD defined kidney outcomes as primary and demonstrated substantial kidney benefits of SGLT2i3.”
§ Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial > Abstract
What the sources say
- Supportedcites [3] Nuffield Department of Population Health Renal Studies Group. SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists’ Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet 400, 1788–1801 (2022). source
The Results report that SGLT2 inhibitors reduced cardiovascular death or hospitalisation for heart failure compared with placebo. They also report reduced kidney disease progression in the chronic kidney disease trials. These findings support the attributed claim about SGLT2 inhibitors; this verdict does not assess the sentence’s separate claim about GLP-1 receptor agonists. (LLM, conf=0.93)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Main · boosted
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In the three kidney outcomes trials examining SGLT2i, the use of GLP-1 RAs was rare, below 5%12–14.”
§ Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial > Discussion
What the sources say
- Partly supportedcites [12] Beernink, J. M. et al. Efficacy of dapagliflozin by baseline diabetes medications: a prespecified analysis from the DAPA-CKD study. Diabetes Care 46, 602–607 (2023). sourceExperimental — accuracy not yet measured
The Conclusions state that GLP-1 receptor agonist use in DAPA-CKD was low. Our copy does not establish that use was below 5% in DAPA-CKD or report GLP-1 receptor agonist use across all three kidney outcomes trials. (LLM, conf=0.86)
- Could not verifycites [13] Perkovic, V. et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N. Engl. J. Med. 380, 2295–2306 (2019). sourceExperimental — accuracy not yet measured
The Methods and Patients sections identify CREDENCE as a kidney-outcomes trial of an SGLT2 inhibitor, but the baseline characteristics shown in our copy do not report GLP-1 receptor agonist use. Searches for GLP-1 receptor agonists, baseline use, and the below-5% figure found no passage establishing that rate for CREDENCE or the three trials. (LLM, conf=0.73)
- Could not verifycites [14] Herrington, W. G. et al. Empagliflozin in patients with chronic kidney disease. N. Engl. J. Med. 388, 117–127 (2023). sourceExperimental — accuracy not yet measured
The Discussion identifies EMPA-KIDNEY alongside CREDENCE and DAPA-CKD as three CKD trials of SGLT2 inhibitors, but it gives no GLP-1 receptor agonist use rates. Searches for GLP-1, glucagon-like peptide-1 receptor agonists, and baseline medication use found no passage establishing the claimed below-5% figure. (LLM, conf=0.73)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The authors concluded that the combination of both drug classes was associated with a lower risk of MACE and serious kidney disease events compared with either drug class alone.”
- Also stated in: § Discussion · plain
“That conclusion is supported by other reviews and meta-analyses10,11.”
§ Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial > Discussion
What the sources say
- Supportedcites [9] Simms-Williams, N. et al. Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study. BMJ 385, e078242 (2024). source
The paper’s Conclusions state that the combination was associated with lower risks of major adverse cardiovascular events and serious renal events than either drug class alone. The Results qualify the renal comparison with SGLT-2 inhibitors alone: its confidence interval was wide and included no difference. (LLM, conf=0.93)
- Not checked — no full text of the sourcecites [10] van Raalte, D. H. et al. Combination therapy for kidney disease in people with diabetes mellitus. Nat. Rev. Nephrol. 20, 433–446 (2024). source
- Partly supportedcites [11] Ahmad, A. & Sabbour, H. Effectiveness and safety of the combination of sodium–glucose transport protein 2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of observational studies. Cardiovasc. Diabetol. 23, 99 (2024). sourceExperimental — accuracy not yet measured
The Introduction and Discussion report lower MACE risk with combination therapy than with monotherapy, although the paper attributes that finding to earlier studies rather than to its own pooled analysis. The Results (Renal outcomes; page not provided) report eGFR and albuminuria findings, but do not establish a lower risk of serious kidney disease events compared with either drug class alone. Thus the claimed conclusion is only partly supported. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Discussion · plain
36 more claims · 1 with their cited sources checked
Create a free account to see all 83 claims and every source verdict.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 15
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“semaglutide can reduce the progression of chronic kidney disease in patients with and without diabetes and even in those taking SGLT2 inhibitors [12–14].”
From New drugs for the treatment of obesity: do we need approaches to preserve muscle mass? (2025) · cites this paper as [14]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Concomitant use of SGLT2 inhibitor with GLP-1 RA did not affect the overall benefits of semaglutide on kidney and cardiovascular outcomes in participants with type 2 diabetes and CKD in a prespecified analysis of the FLOW trial; however, the limited use of SGLT2 inhibitors at baseline may have affected these results (147).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [147]
Citations
Cites
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Self-citation(2013) · Kidney International Supplements · doi:10.1038/kisup.2012.73 · Cited by 3,206
Empagliflozin in Patients with Chronic Kidney Disease
The EMPA-KIDNEY Collaborative Group (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2204233 · Cited by 2,754 · cited 1×
“In the three kidney outcomes trials examining SGLT2i, the use of GLP-1 RAs was rare, below 5% 12–14 .”
BackgroundEffects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
Perkovic, V., Tuttle, K. R., Rossing, P., Mahaffey, K. W., Mann, J. F. E., Bakris, G., Baeres, F. M. M., Idorn, T., Bosch-Traberg, H., Lausvig, N. L., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2403347 · Cited by 2,099
Self-citationKristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., Køber, L., Petrie, M. C., & McMurray, J. J. V. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30249-9 · Cited by 1,663
Sattar, N., Lee, M. M. Y., Kristensen, S. L., Branch, K. R. H., Del Prato, S., Khurmi, N. S., Lam, C. S. P., Lopes, R. D., McMurray, J. J. V., Pratley, R. E., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00203-5 · Cited by 1,599 · cited 2×
“Notably, GLP-1 RAs, including semaglutide, also provide substantial benefits for CV and CKD outcomes, death 1,2 and heart failure 5 .”
BackgroundSelf-citationBaigent, C., Emberson, J., Haynes, R., Herrington, W. G., Judge, P., Landray, M. J., Mayne, K. J., Ng, S. Y. A., Preiss, D., Roddick, A. J., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)02074-8 · Cited by 1,020
Self-citationMolecular mechanisms and therapeutic targets for diabetic kidney disease
Tuttle, K. R., Agarwal, R., Alpers, C. E., Bakris, G. L., Brosius, F. C., Kolkhof, P., & Uribarri, J. (2022) · Kidney International · doi:10.1016/j.kint.2022.05.012 · Cited by 668 · cited 1×
“Since the molecular mechanisms of action of both drug classes on the CV system and the kidney may be complementary and largely independent of glucose lowering 6 , it has been speculated that the combination might further improve clinical outcomes.”
BackgroundSelf-citationDiabetic Nephropathy: Update on Pillars of Therapy Slowing Progression
Naaman, S. C., & Bakris, G. L. (2023) · Diabetes Care · doi:10.2337/dci23-0030 · Cited by 292
Self-citationRossing, P., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.06.013 · Cited by 274
Self-citation
Research works printed but not linked: 1
- Neuen, B. Efficacy and safety of SGLT2 inhibitors with and without GLP-1 receptor agonists: a SMART-C collaborative meta-analysis. Nephrol. Dial. Transpl. 39, e061807 (2024).
Cited by
Type 2 diabetes mellitus in adults: pathogenesis, prevention and therapy
Lu, X., Xie, Q., Pan, X., Zhang, R., Zhang, X., Peng, G., Zhang, Y., Shen, S., & Tong, N. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01951-9 · Cited by 665
GLP-1-based therapies for diabetes, obesity and beyond
Drucker, D. J. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01183-8 · Cited by 236
“The benefits of semaglutide in the FLOW trial were observed independent of the presence or absence of concomitant use of SGLT-2 inhibitors at baseline 119 .”
Neuen, B. L., Fletcher, R. A., Heath, L., Perkovic, A., Vaduganathan, M., Badve, S. V., Tuttle, K. R., Pratley, R., Gerstein, H. C., Perkovic, V., et al. (2024) · Circulation · doi:10.1161/circulationaha.124.071689 · Cited by 168
Self-citationCardiovascular disease in chronic kidney disease
Marx-Schütt, K., Cherney, D. Z. I., Jankowski, J., Matsushita, K., Nardone, M., & Marx, N. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf167 · Cited by 185
“70 A recent meta-analysis of CVOTs with GLP-1 RA including FLOW and SELECT suggests that GLP-1 RA reduce kidney disease progression in T2DM or over-weight/obesity regardless of CKD status.”
Apperloo, E. M., Gorriz, J. L., Soler, M. J., Cigarrán Guldris, S., Cruzado, J. M., Puchades, M. J., López-Martínez, M., Waanders, F., Laverman, G. D., van der Aart-van der Beek, A., et al. (2025) · Nature Medicine · doi:10.1038/s41591-024-03327-6 · Cited by 120
“Specifically, a pre-specified analysis of the FLOW trial showed consistent benefits on UACR, eGFR decline and clinical outcomes in participants using or not using SGLT2 inhibitors at baseline 24 .”
Self-citation
Metadata
- Authors
- Mann, J. F. E., Rossing, P., Bakris, G., Belmar, N., Bosch-Traberg, H., Busch, R., Charytan, D. M., Hadjadj, S., Gillard, P., Górriz, J. L., Idorn, T., Ji, L., Mahaffey, K. W., Perkovic, V., Rasmussen, S., Schmieder, R. E., Pratley, R. E., & Tuttle, K. R.
- Affiliations
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- University of Copenhagen (DK)
- University of Chicago (US)
- Novo Nordisk (Denmark) (DK)
- Albany Medical Center Hospital (US)
- NYU Langone Health (US)
- Centre National de la Recherche Scientifique (FR)
- KU Leuven (BE)
- Universitat de València (ES)
- Peking University People's Hospital (CN)
- Stanford Medicine (US)
- UNSW Sydney (AU)
- AdventHealth Orlando (US)
- University of Washington (US)
- Corresponding author
- Mann, Johannes F. E.
- ORCID
- Venue
- Nature Medicine
- Published
- 2024-06-24
- Volume
- 30
- Issue
- 10
- Pages
- 2849-2856
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC11485243
- OpenAlex
- W4399940216
- Cited by
- 200
- References
- 23
- Citations by year
- 2026: 78 · 2025: 87 · 2024: 35
- FWCI
- 65.42
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by)
- HAL (submittedVersion, cc-by)
- Lirias (KU Leuven) (submittedVersion, cc-by)
- Repository of Digital Objects for Teaching Research and Culture (University of Valencia) (submittedVersion, other-oa)
- Funders
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- semaglutide, SGLT2 inhibitors, type 2 diabetes, chronic kidney disease, GLP-1 receptor agonists, renal failure, estimated glomerular filtration rate decline, cardiovascular events, all-cause mortality, combination therapy, FLOW trial, drug interactions, cardiovascular safety, renal safety, glycemic control, blood pressure
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Semaglutide, Aged, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Female, Glomerular Filtration Rate, Humans, Hypoglycemic Agents, Male, Middle Aged, Treatment Outcome, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-16, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-16 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial. https://app.cochat.ai/papers/10.1038/s41591-024-03133-0
- The paper
- Mann, J. F. E., Rossing, P., Bakris, G., Belmar, N., Bosch-Traberg, H., Busch, R., Charytan, D. M., Hadjadj, S., Gillard, P., Górriz, J. L., Idorn, T., Ji, L., Mahaffey, K. W., Perkovic, V., Rasmussen, S., Schmieder, R. E., Pratley, R. E., & Tuttle, K. R. (2024). Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial. Nature Medicine. https://doi.org/10.1038/s41591-024-03133-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.